Financials data is unavailable for this security.
View more
Year on year Innovent Biologics Inc grew revenues 36.21% from 4.56bn to 6.21bn while net income improved from a loss of 2.18bn to a smaller loss of 1.03bn.
Gross margin | 82.44% |
---|---|
Net profit margin | -17.18% |
Operating margin | -16.02% |
Return on assets | -6.71% |
---|---|
Return on equity | -11.04% |
Return on investment | -8.22% |
More ▼
Cash flow in CNYView more
In 2023, Innovent Biologics Inc increased its cash reserves by 170.20%, or 1.73bn. Cash Flow from Financing totalled 2.59bn or 41.69% of revenues. In addition the company generated 147.81m in cash from operations while cash used for investing totalled 998.66m.
Cash flow per share | -0.6008 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 8.30 |
---|---|
Tangible book value per share | 7.64 |
More ▼
Balance sheet in CNYView more
Current ratio | 2.68 |
---|---|
Quick ratio | 2.51 |
Total debt/total equity | 0.2695 |
---|---|
Total debt/total capital | 0.2123 |
More ▼